dostęp otwarty
Hiperurykemia w chorobach układu sercowo-naczyniowego
- Katedra i Zakład Farmakologii i Terapii, Collegium Medicum w Bydgoszczy, Uniwersytet Mikołaja Kopernika w Toruniu
- Katedra Kardiologii i Chorób Wewnętrznych, Szpital Uniwersytecki nr 1 im. dr. A. Jurasza ul. Curie Skłodowskiej 9, 85-094 Bydgoszcz, Polska
- Przychodnia Ogrody Sp. z o.o., ul. Ogrody 21, 85-870 Bydgoszcz, Polska
dostęp otwarty
Streszczenie
Streszczenie
Słowa kluczowe
kwas moczowy, hiperurykemia, choroby sercowo-naczyniowe, ryzyko sercowo-naczyniowe, allopurynol
Tytuł
Hiperurykemia w chorobach układu sercowo-naczyniowego
Czasopismo
Numer
Strony
116-124
Opublikowany online
2019-06-04
Wyświetlenia strony
2297
Wyświetlenia/pobrania artykułu
2532
Rekord bibliograficzny
Forum Medycyny Rodzinnej 2019;13(3):116-124.
Słowa kluczowe
kwas moczowy
hiperurykemia
choroby sercowo-naczyniowe
ryzyko sercowo-naczyniowe
allopurynol
Autorzy
Wioleta Stolarek
Damian Stolarek
- McQuillan GM, McLean JE, Chiappa M, et al. National Health and Nutrition Examination Survey Biospecimen Program: NHANES III (1988-1994) and NHANES 1999-2014. Vital Health Stat 2. 2015(170): 1–14.
- Richet G. The chemistry of urinary stones around 1800: a first in clinical chemistry. Kidney Int. 1995; 48(3): 876–886.
- Battelli MG, Polito L, Bolognesi A. Xanthine oxidoreductase in atherosclerosis pathogenesis: not only oxidative stress. Atherosclerosis. 2014; 237(2): 562–567.
- Pasalic D, Marinkovic N, Feher-Turkovic L. Uric acid as one of the important factors in multifactorial disorders--facts and controversies. Biochem Med (Zagreb). 2012; 22(1): 63–75.
- Kushiyama A, Tanaka K, Hara S, et al. Linking uric acid metabolism to diabetic complications. World J Diabetes. 2014; 5(6): 787–795.
- Zimmermann-Górska I. Choroby związane z obecnością kryształów . In: Gajewski P. ed. Interna Szczeklika. Medycyna Praktyczna, Kraków 2016: 2027–2034.
- Maiuolo J, Oppedisano F, Gratteri S, et al. Regulation of uric acid metabolism and excretion. Int J Cardiol. 2016; 213: 8–14.
- Narang RK, Topless R, Cadzow M, et al. Eurogout Consortium, Eurogout Consortium. Gout. Lancet. 2016; 388(10055): 2039–2052.
- Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000; 27(6): 1501–1505.
- Norvik JV, Storhaug HM, Ytrehus K, et al. Overweight modifies the longitudinal association between uric acid and some components of the metabolic syndrome: The Tromsø Study. BMC Cardiovasc Disord. 2016; 16: 85.
- Singh JA. Racial and gender disparities among patients with gout. Curr Rheumatol Rep. 2013; 15(2): 307.
- Zhang L, Spencer KL, Voruganti VS, et al. Association of functional polymorphism rs2231142 (Q141K) in the ABCG2 gene with serum uric acid and gout in 4 US populations: the PAGE Study. Am J Epidemiol. 2013; 177(9): 923–932.
- Zimmermann-Gorska I. Aktualne możliwości leczenia chorych na dnę moczanową. Reumatologia. 2009; 47(2): 75–81.
- Martynowicz H, Szuba A. Najczęstsze działania niepożądane leków hipotensyjnych – jak sobie z nimi radzić? Medycyna po Dyplomie. 2011; 20(9): 29–34.
- Reyes AJ. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther. 2003; 17(5-6): 397–414.
- Krishnan E. Reduced glomerular function and prevalence of gout: NHANES 2009-10. PLoS One. 2012; 7(11): e50046.
- Feig DI, Kang DH, Johnson RJ, et al. Diuretic-induced hyperuricemia does not decrease cardiovascular risk. J Hypertens. 2004; 22(7): 1415–1417.
- Glantzounis GK, Tsimoyiannis EC, Kappas AM, et al. Uric acid and oxidative stress. Curr Pharm Des. 2005; 11(32): 4145–4151.
- Abeles AM. Hyperuricemia, gout, and cardiovascular disease: an update. Curr Rheumatol Rep. 2015; 17(3): 13.
- Sautin YY, Johnson RJ. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids. 2008; 27(6): 608–619.
- Ioachimescu AG, Brennan DM, Hoar BM, et al. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum. 2008; 58(2): 623–630.
- Perlstein TS, Gumieniak O, Williams GH, et al. Uric acid and the development of hypertension: the normative aging study. Hypertension. 2006; 48(6): 1031–1036.
- Syamala S, Li J, Shankar A. Association between serum uric acid and prehypertension among US adults. J Hypertens. 2007; 25(8): 1583–1589.
- Enomoto A, Endou H. Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clin Exp Nephrol. 2005; 9(3): 195–205.
- Perez-Ruiz F, Becker MA. Inflammation: a possible mechanism for a causative role of hyperuricemia/gout in cardiovascular disease. Curr Med Res Opin. 2015; 31 Suppl 2: 9–14.
- Kucharz EJ. Chronic inflammation-enhanced atherosclerosis: can we consider it as a new clinical syndrome? Med Hypotheses. 2012; 78(3): 396–397.
- Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007; 120(5): 442–447.
- Sicras-Mainar A, Navarro-Artieda R, Ibáñez-Nolla J. Resource use and economic impact of patients with gout: a multicenter, population-wide study. Reumatol Clin. 2013; 9(2): 94–100.
- Quiñones Galvan A, Natali A, Baldi S, et al. Effect of insulin on uric acid excretion in humans. Am J Physiol. 1995; 268(1 Pt 1): E1–E5.
- Feig DI, Kang DH, Nakagawa T, et al. Uric acid and hypertension. Curr Hypertens Rep. 2006; 8(2): 111–115.
- Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol. 2007; 18(1): 287–292.
- Keil U. The Worldwide WHO MONICA Project: results and perspectives. Gesundheitswesen. 2005; 67 Suppl 1: S38–S45.
- Riddle DL, Johnson RE, Jensen MP, et al. The Pragmatic-Explanatory Continuum Indicator Summary (PRECIS) instrument was useful for refining a randomized trial design: experiences from an investigative team. J Clin Epidemiol. 2010; 63(11): 1271–1275.
- Brand FN, McGee DL, Kannel WB, et al. Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am J Epidemiol. 1985; 121(1): 11–18.
- Pak S, Yatsynovich Y, Valencia D, et al. Serum Uric Acid and Atrial Fibrillation: Meta-analysis. Crit Pathw Cardiol. 2018; 17(3): 161–166.
- Widecka K, Grodzicki T, Narkiewicz K. Zasady postępowania w nadciśnieniu tętniczym — 2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze. 2011; 15: 55–82.
- Mancia G, Fagard R, Narkiewicz K, et al. Wytyczne ESH/ESC dotyczące postępowania w nadciśnieniu tętniczym w 2013 roku. Nadciśnienie Tętnicze. 2013; 17(2): 69–168.
- Tykarski A, Narkiewicz K, Gaciong Z, et al. Guidelines for the Management of Hypertension. Arterial Hypertension. 2015; 19(2): 53–83.
- Høieggen A, Alderman MH, Kjeldsen SE, et al. LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004; 65(3): 1041–1049.
- Kelkar A, Kuo A, Frishman WH. Allopurinol as a cardiovascular drug. Cardiol Rev. 2011; 19(6): 265–271.
- Milurit-charakterystyka produktu leczniczego. www.egis.pl/pobierz/ 69/milurit-charakterystyka-produktu-leczniczego (5.11.2014).
- Kumar A, Edward N, White MI, et al. Allopurinol, erythema multiforme, and renal insufficiency. BMJ. 1996; 312(7024): 173–174.
- Terkeltaub RA. Clinical practice. Gout. N Engl J Med. 2003; 349(17): 1647–1655.
- Luk AJ, Levin GP, Moore EE, et al. Allopurinol and mortality in hyperuricaemic patients. Rheumatology (Oxford). 2009; 48(7): 804–806.
- Dubreuil M, Zhu Y, Zhang Y, et al. Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis. 2015; 74(7): 1368–1372.
- Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2013; 15(6): 435–442.
- Qu LH, Jiang H, Chen JH. Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis. Ann Med. 2017; 49(2): 142–156.
- Deng G, Qiu Z, Li D, et al. Effects of allopurinol on arterial Stiffness: a meta-analysis of randomized controlled trials. Med Sci Monit. 2016; 22: 1389–1397.
- Bruce SP. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother. 2006; 40(12): 2187–2194.
- Nazwa produktu leczniczego Adenuric 80 mg. www.berlin-chemie pl./Adenuric_80mg_ (8.04.2015).
- White WB, Saag KG, Becker MA, et al. CARES Investigators. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018; 378(13): 1200–1210.
- Borghi C, Tykarski A, Widecka K, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. Cardiol J. 2018; 25(5): 545–563.
- Scirè CA, Rossi C, Punzi L, et al. Change gout: how to deal with this "silently-developing killer" in everyday clinical practice. Curr Med Res Opin. 2018; 34(8): 1411–1417.
- Saag KG, Fitz-Patrick D, Kopicko J, et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis Rheumatol. 2017; 69(1): 203–212.
- Jones G, Panova E, Day R. Guideline development for the management of gout: role of combination therapy with a focus on lesinurad. Drug Des Devel Ther. 2017; 11: 3077–3081.
- Huneycutt E, Board C, Clements JN. Lesinurad, a selective URAT-1 inhibitor with a novel mechanism in combination with a xanthine oxidase inhibitor, for hyperuricemia associated with gout. J Pharm Pract. 2017 [Epub ahead of print]: 897190017734427.
- Khanna D, Fitzgerald JD, Khanna PP, et al. American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012; 64(10): 1431–1446.